Unlike growth hormone peptides (which work through the pituitary) or GLP-1 peptides (which work through gut and brain receptors), BPC-157 works primarily through a different mechanism: it upregulates growth hormone receptors in tendon cells, stimulates angiogenesis (the formation of new blood vessels), and modulates nitric oxide signaling all of which contribute to accelerated tissue repair and reduced inflammation
It is in the same family of drugs (incretin-based pharmacotherapy for weight and metabolic disease) but it acts on three receptors rather than one
Baseline characteristics of case and control subjects after matching Values are presented as meanstandard deviation or number (%)
Variants in the GLP1R gene (rs6923761) and MC4R gene (rs17782313) affect your metabolic rate, immune signaling, and appetite regulation
These medications work by enhancing insulin secretion, suppressing glucagon release, slowing gastric emptying, and reducing appetite